本帖最后由 老马 于 2013-3-13 13:43 编辑 5 s$ i! u3 k7 V; K5 \6 v4 a. o# e
3 G5 @0 `' W! D- G- o( E健择(吉西他滨)+顺铂+阿瓦斯汀, U- c$ h+ ^* H( R6 i+ G) P$ y
Gemzar +Cisplatin + Avastin
$ P# e/ d# @: I6 t/ w, y1 c4 ihttp://annonc.oxfordjournals.org/content/21/9/1804.full
: s5 Y" x$ w$ {+ C- COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) \; C- |+ f- M9 V% TPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 1 ] N( T$ {3 P5 e- |
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ! _3 [- r' w! K5 y9 Y2 L
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 632)
' l/ y. L, M% k9 q& m% `6 E华为网盘附件:
9 K5 V# Q9 u$ I+ d【华为网盘】ava.JPG. R9 @2 m9 Q8 i
|